Navigation Links
Transgene: Cash Position of EUR 119 Million as of September 30, 2007
Date:10/10/2007

STRASBOURG, France, October 10 /PRNewswire-FirstCall/ -- Transgene S.A. (Eurolist Paris: FR0005175080) announces that cash, cash equivalents and short term investments totaled EUR 119 million at September 30, 2007 compared to EUR 114.3 million at June 30, 2007 (unaudited figures, IAS/IFRS).

For the first nine months of 2007, cash, cash equivalents and short term investments increased by EUR 98.7 million. This was mainly due to payments received from the partnership agreement with Roche (EUR 23 million), the capital increase carried out in June and July 2007 (net proceeds: EUR 95.3 million) and cash expenditures of EUR 19.6 million.

About Transgene:

Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has one product which has completed Phase II trials (TG4001/R3484), two compounds in Phase II trials (TG4010 and TG1042) and one compound in Phase I studies (TG4040). Transgene has concluded a strategic partnership agreement with Roche for the development of its TG4001/R3484 therapeutic vaccine to treat HPV-mediated diseases. Transgene has bio-manufacturing capacities for viral-based vectors and technologies available for out-licensing. Additional information about Transgene is available on the Internet at http://www.transgene.fr.


'/>"/>
SOURCE Transgene S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
2. Wisconsin early-stage companies must position themselves to get capital
3. New UW position focusing on Internet security
4. Midwest holds strong position in worldwide diagnostics business
5. Doyle praises Frists new stem cell research position
6. GE promotes Milwaukee-area CEO to London position
7. Is IT leadership a position or an attitude?
8. nPoint announces new nanopositioning scanning control mode
9. Venture Investors early-stage fund grows to $115 million
10. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
11. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
Breaking Biology Technology:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):